CRISPR-Cas9 Market By Type (Grna Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, and Cell Line Engineering), By Application (Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, and Research & Development Institutes), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

CRISPR is a family of DNA sequences present in the genomes of prokaryotic organisms such as bacteria and archaea.CRISPR-Cas9 is a technology that enables medical researchers to edit parts of the genome by altering, adding or removing sections of the DNA sequence. CRISPR/Cas9 system consists of two parts the Cas9 enzyme and a guide RNA. Cas9 enzyme acts as a pair of molecular scissors, which is capable of cutting strands of DNA. A guide RNA is designed to find and bind specific sequence in the DNA. CRISPR potential applications include treating and preventing the spread of diseases and improving crops and correcting genetic defects.

CRISPR-Cas9 market is estimated to reach $9 billion by 2030; growing at a CAGR of 17.5% till 2030

Market Determinants

Increasing government initiatives to enhance precision medicine for precise cure and treatment is a key driving factor of the market. For instance, the California government has introduced the bipartisan Advancing Access to Precision Medicine Act, to push forward the use of genetic and genomic testing to improve and save lives. The governor of California has funded USD 30 million to establish the California Institute to Advance Precision Health and Medicine. Moreover, the U.S government has initiated Precision Medicine Initiative by investing USD 215 million aiming for better health for the people by transforming the treatment process as precision medicine directly targets the gene of the person and modify the DNA sequence to cure and for better treatment. Additionally, The US National Institutes of Health (NIH) has funded USD190 million for genome editing research. The Somatic Cell CRISPR-Cas9, which is supported by the NIH Common Fund. However, CRISPR-Cas9 can result in an undesired aberrant phenotype, which might hamper the market growth. For instance, CRISPR-Cas9 can alter the function of a gene and result in genomic instability, hindering it prospective and application in the clinical procedure. CRISPR/Cas9 is not 100% precision, and if off-targets occur upon engineering the genome, this can result in undesired aberrant phenotype. Increasing clinical trials for testing CRISPR-Cas9 and undefined would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global CRISPR-Cas9 market is mainly classified based on Type, Application. Type is further segmented into Grna Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering. Grna Database is a genome-wide gRNA library design tool for Cas9 nucleases from Streptococcus pyogenes (SpCas9). It contains all targets of SpCas9 nucleases that recognizes 5’-NGG-3’ PAM sequences in all coding sequence (CDS) regions.Grna Database also provides a web application programming interface (web API) for information about advanced use. Grna Database/Gene Library is the dominant segment and accounted for approximately 36.45% of the market in 2018, due to the competitive advancement between companies to produce and commercialize CRISPR lenti-gRNA libraries. Further, by Application, the market is divided into Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes.

Regional Analysis

Based on geography, the global CRISPR-Cas9 market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. North America is dominating the global CRISPR-Cas9 market and account for 47.34% of market share, due to regulatory approvals for testing the CRISPR genome editing technology. For instance, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EDIT-101.

Market Leaders

Key players operating in the CRISPR-Cas9 industry include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, IntelliaTherapeutics, Inc., Horizon Discovery Plc, Sigma Aldrich, Genscript, Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies.

Formation of strategic collaborations and government funding to the companies are the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The companies are focused on product approvals and expansion of business activities on a global scale. For instance,in August 2017, CRISPR Therapeutics has entered into a research collaboration and license option agreement for 2 years with Massachusetts General Hospital Cancer Center (MGHCC), to develop novel T cell therapies for cancer, with the CRISPR/Cas9 gene-editing utilized to improve upon current T cell therapies in development, addressing unmet needs in both hematologic and solid tumors.

CRISPR-Cas9 Market Key Segments

By Type
• Grna Database/Gene Librar
• CRISPR Plasmid
• Human Stem Cells
• Genetically Modified Organisms/Crops
• Cell Line Engineering

By Application
• Biotechnology Companies
• Pharmaceutical Companies
• Academic Institutes
• Research and Development Institutes

By Geography

• North America
o The U.S.
o Canada
o Mexico
• Europe
o U.K
o Germany
o France
o Italy
o Rest of Europe
• Asia Pacific
o India
o China
o Japan
o South Korea
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Rest of South America
• Middle East & Africa
o GCC Countries
o Egypt
o South Africa
o Rest of Middle East & Africa

Key Global CRISPR-Cas9 Industry Players

• Thermo Fisher Scientific
• Editas Medicine
• Caribou Biosciences
• CRISPR Therapeutics
• IntelliaTherapeutics, Inc.
• Horizon Discovery Plc
• Sigma Aldrich
• Genscript
• Lonza Group Limited
• Integrated DNA Technologies
• New England Biolabs
• Origene Technologies

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. CRISPR-Cas9 Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing government initiatives to enhance precision medicine for precise cure and treatment
3.4. Restraints
3.4.1. CRISPR-Cas9 can result inan undesired aberrant phenotype
3.5. Opportunity
3.5.1. Increasing clinical trials for testing CRISPR-Cas9
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Grna Database/Gene Librar
4.2.1. Market Size & Forecast
4.3. CRISPR Plasmid
4.3.1. Market Size & Forecast
4.4. Human Stem Cells
4.4.1. Market Size & Forecast
4.5. Genetically Modified Organisms/Crops
4.5.1. Market Size & Forecast
4.6. Cell Line Engineering
4.6.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Biotechnology Companies
5.2.1. Market Size & Forecast
5.3. Pharmaceutical Companies
5.3.1. Market Size & Forecast
5.4. Academic Institutes
5.4.1. Market Size & Forecast
5.5. Research and Development Institutes
5.5.1. Market Size & Forecast

6. CRISPR-Cas9 Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America CRISPR-Cas9 Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe CRISPR-Cas9 Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific CRISPR-Cas9 Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America CRISPR-Cas9 Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa CRISPR-Cas9 Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Thermo Fisher Scientific
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Thermo Fisher Scientific Product Category, Application, and Specification
7.1.3. Thermo Fisher Scientific Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Editas Medicine
7.3. Caribou Biosciences
7.4. CRISPR Therapeutics
7.5. IntelliaTherapeutics, Inc.
7.6. Horizon Discovery Plc
7.7. Sigma Aldrich
7.8. Genscript
7.9. Lonza Group Limited
7.10. Integrated DNA Technologies
7.11. New England Biolabs
7.12. Origene Technologies